Related Experiment Videos
Cytomegalovirus colitis and wasting
1Department of Medicine, Columbia University, New York, New York.
Journal of Acquired Immune Deficiency Syndromes
|January 1, 1991
Summary
Ganciclovir treatment significantly improved body mass and energy in AIDS patients with cytomegalovirus (CMV) infection. This suggests ganciclovir can help combat wasting and prolong survival in these individuals.
Area of Science:
- Infectious Diseases
- Immunology
- Oncology
Background:
- Disseminated cytomegalovirus (CMV) infection is a severe complication in patients with acquired immune deficiency syndrome (AIDS).
- CMV infection in AIDS patients leads to significant depletion of body cell mass, body fat, and overall energy stores, contributing to wasting syndrome.
Purpose of the Study:
- To investigate the efficacy of ganciclovir in mitigating wasting associated with disseminated CMV infection in AIDS patients.
- To assess the impact of ganciclovir treatment on body composition and energy content in this patient population.
Main Methods:
- A comparative study was conducted on AIDS patients diagnosed with disseminated CMV infection.
- Patients were divided into two groups: one receiving ganciclovir treatment and a control group not receiving ganciclovir.
- Body cell mass, body fat, body weight, and total body energy content were measured and compared between the groups.
Main Results:
- Patients treated with ganciclovir demonstrated significant improvements in body cell mass, body fat, body weight, and total body energy content compared to the control group.
- The repletion of body cell mass was a key finding in the ganciclovir-treated cohort.
Conclusions:
- Ganciclovir treatment is effective in reversing wasting and improving body composition in AIDS patients with disseminated CMV infection.
- Successful ganciclovir therapy for CMV infection in AIDS patients is associated with enhanced quality of life and extended survival.